...
RCUSMID

Arcus Biosciences, Inc.

HealthcareBiotechnology
$20.37
$0.01(+4.25%)
52W$6.50
$26.40
FinancialsValuationvs RVMD
Updated Mar 2, 12:00 AM
RSI44
RS Rating88/99
Beta1.37
Volatility63%
F-Score0/9
Mkt Cap$2.6B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Arcus Biosciences, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is leading (RS Rating: 88), indicating clear outperformance against the broad market. Earnings growth of 10% provides fundamental context to the price action. Investors should exercise caution due to high volatility (63% annualized), which requires wider risk management.

Relative Strength
88
out of 99
Market Leader
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
1.37
vs S&P 500
ABOVE MKT
52W Position
70%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$21.58
50 SMA > 100 SMA$21.01
100 SMA > 150 SMA$17.71
150 SMA > 200 SMA$15.55

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$20.24+0.65%ABOVE
50 SMA$21.58-5.63%BELOW
100 SMA$21.01-3.06%BELOW
150 SMA$17.71+15.03%ABOVE
200 SMA$15.55+31.03%ABOVE

Price Performance

1D+4.2%
1W+8.1%
1M-6.1%
3M-22.0%
6M+92.0%
YTD-12.5%
1Y+87.1%
3Y+3.8%
52-Week Trading Range70% from low
$20.37
52W Low$6.50
52W High$26.40

Technical Indicators

RSI (14)NEUTRAL
43.5
305070
VCP ScoreCOOL
3/10
Base depth: 38.7%

Risk Profile

Beta
1.37
52W Vol
63%
ATR
$1.22
Max DD (1Y)
-37%

Volume Analysis

Today
20
50D Avg
997.3K
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q1'25-2357%
$-1.14
Q2'25+104%
$0.04
Q3'25-26%
$-1.27
Q4'25+10%
$-0.92
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:+25.93%
3 Years:+30.16%
TTM:-4.26%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-5.91%

Stock Price CAGR

10 Years:+1.82%
5 Years:-11.11%
3 Years:+3.81%
1 Year:+87.05%

Return on Equity

10Y Avg:-37.1%
5Y Avg:-41.1%
3Y Avg:-59.3%
Last Year:-55.9%

Key Metrics

Market Cap$2.6B
Gross Margin—
Net Margin-1.4%
Piotroski F-Score0/9

More RCUS Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

RCUS vs RVMDRVMDINCYGMABEXEL

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 88 meansRCUS outperformed 88% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.37 means 37% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 0/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 3/10 with COOL status.

Frequently Asked Questions

Is RCUS in an uptrend right now?

RCUS has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is RCUS overbought or oversold?

RCUS's RSI (14) is 44. The stock is in neutral territory, neither overbought nor oversold.

Is RCUS outperforming the market?

RCUS has a Relative Strength (RS) Rating of 88 out of 99. Yes, RCUS is a market leader, outperforming 88% of all stocks over the past 12 months.

Where is RCUS in its 52-week range?

RCUS is trading at $20.37, which is 77% of its 52-week high ($26.40) and 70% above its 52-week low ($6.50).

How volatile is RCUS?

RCUS has a Beta of 1.37 and 52-week volatility of 63%. It's more volatile than the S&P 500 - expect bigger swings.